Sunho Biologics Inc

02898

Company Profile

  • Business description

    Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

  • Contact

    No. 198 Peninsula Middle Road, Dipu Street
    Room 302, Building 3
    Anji County
    Zhejiang Province
    Huzhou
    CHN

    http://www.sunho-bio.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    128

Stocks News & Analysis

stocks

Navigating the ASX dividend landscape in 2026

Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks

Meta stock has struggled amid AI spending concerns. Is it a buy?

Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks

Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth

We think Netflix stock is moderately overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,172.5012.400.14%
CAC 408,166.1396.961.20%
DAX 4024,877.52316.541.29%
Dow JONES (US)49,072.24583.651.20%
FTSE 10010,209.9271.830.71%
HKSE26,597.4912.430.05%
NASDAQ23,224.82270.501.18%
Nikkei 22553,688.89914.251.73%
NZX 50 Index13,556.8717.06-0.13%
S&P 5006,873.7776.911.13%
S&P/ASX 2008,848.7012.800.14%
SSE Composite Index4,122.585.640.14%

Market Movers